U.S. markets open in 6 hours 38 minutes

Vaccinex, Inc. (VCNX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.8100-0.0390 (-4.59%)
At close: 04:00PM EST
0.8099 -0.00 (-0.01%)
After hours: 04:51PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close0.8490
Bid0.0000 x 1000
Ask0.0000 x 1200
Day's Range0.7906 - 0.8500
52 Week Range0.7700 - 12.3000
Avg. Volume660,908
Market Cap10.12M
Beta (5Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-5.9900
Earnings DateNov 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VCNX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Vaccinex, Inc.
    Daily – Vickers Top Insider Picks for 11/29/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    19 hours agoArgus Research
View more
  • GlobeNewswire

    Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

    Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new financing during Q3 and early October 2023. ROCHESTER, N.Y., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial r

  • GlobeNewswire

    Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

    Pepinemab, anti-SEMA4D blocking antibody, appears to enhance clinical activity of immune checkpoint inhibitors via induction of highly organized tertiary immune structures in tumors of patients with head and neck cancer and melanomaROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two presentations at the 38th Annual Meeting of the Society for Immunotherapy

  • GlobeNewswire

    Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

    Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP in patient bloodROCHESTER, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, today reports novel findings for its lead product, pepinemab, in a highlighted podium presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, MA. Vaccinex has previously re